Leveraging Real-World Treatment Experience from EA Protocols

See Event Highlights and Download the Meeting Report 

Monday, November 19, 2018   |  10:00 AM to 4:30 PM

U.S. Food and Drug Administration
White Oak Campus, Building 31, Great Room
10903 New Hampshire Avenue, Silver Spring, MD 20993 

Building on the Reagan-Udall Foundation for the FDA’s work with FDA and other stakeholders to develop the Expanded Access Navigator, we are convening stakeholders from government, industry, academia and patient groups to discuss process issues that include:

  • Increase understanding of the expanded access program
    • Identify and discuss strengths, challenges and opportunities
  • Discuss what could be the optimum balance between providing access for treatment and obtaining data in support of regulatory applications
    • How could the data be leveraged?
    • How could it be optimized without overburdening companies and providers?
  • Provide input to FDA on future communications regarding utilizing data from Expanded Access (investigational) protocols

Agenda

10:00am

Welcome

 

Ellen Sigal, Ph.D., Chair, Board of Directors, Reagan-Udall Foundation for the FDA, and, Chairperson and Founder of Friends of Cancer Research

   

10:05am

Opening Remarks

  Scott Gottlieb, M.D., Commissioner, U.S. Food and Drug Administration (FDA)
   

10:30am

Investigational Therapies and Data Collection

  Janet Woodcock, M.D., Director, Center for Drug Evaluation Research (CDER), FDA
   

10:45am

Panel 1: Patient, Physician, and Bioethics Perspectives

 

Moderator: Richard L. Schilsky, M.D., FACP, FSCT, FASCO, Vice-Chair, Board of Directors, Reagan-Udall Foundation for the FDA, and Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology

Panelists:

Alison Bateman-House, M.P.H., Ph.D., Assistant Professor, Department of Population Health, New York University School of Medicine

Paul Melmeyer, Director of Federal Policy, National Organization for Rare Disorders

Emil Kakkis, M.D., Ph.D., President/CEO, Ultragenyx, and Member, Board of Directors, EveryLife Foundation

   

12:00pm

Lunch Break

   

12:45pm

Panel 2: Industry Case Study Presentations

 

Moderator: Kay Holcombe, Secretary, Board of Directors, Reagan-Udall Foundation for the FDA

Panelists:

David Meeker, M.D., Chief Executive Officer, KSQ Therapeutics

Paul Aliu, Pharm.D., M.B.A., Global Head, Medical Governance, Novartis

Joanne Waldstreicher, M.D., Chief Medical Officer, Johnson & Johnson

Jayne C. Gershkowitz, Chief Patient Advocate, Amicus Therapeutics

   
2:15pm Break
   

2:30pm

Panel 3:  Expanding Impact of Expanded Access 

 

Moderator: Andrew von Eschenbach, M.D., President, Samaritan Health Initiatives Inc., Member, Reagan-Udall Board of Directors, and 20th Commissioner of the FDA

Panelists:

Jacqueline Corrigan-Curay, M.D., J.D., Director, Office of Medical Policy, CDER, FDA

Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research, FDA

Amy McKee, M.D., Deputy Director, Oncology Center of Excellence, FDA

Robert Temple, M.D., Deputy Center Director for Clinical Sciences, CDER, FDA

Peter Stein, M.D., Deputy Director, Office of New Drugs, CDER, FDA

   

4:00pm

Public Comments

   

4:30pm

Closing Remarks

  June Wasser, M.A., Executive Director, Reagan-Udall Foundation for the FDA